Lexicon Pharmaceuticals, Inc. (LXRX) Stock Forecast
LXRX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.17 / 5 from 6 analysts
- Price target
- $4.55 average of analyst targets
- Upside to target
- +199.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.05
- 52-week range
- $1.14 – $2.64
LXRX analyst ratings
6 analystsNumber of analysts at each rating.
LXRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LXRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.06 | −$0.04 | −$0.04 | −32.2% | 3 |
| Current fiscal year (2026) | −$0.17 | −$0.18 | −$0.15 | −$0.14 | −18.8% | 3 |
| Next fiscal year (2027) | −$0.19 | −$0.27 | −$0.11 | −$0.17 | −14.6% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LXRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.1M | $0 | $10.9M | −70.8% | 6 |
| Current fiscal year (2026) | $37.2M | $31.8M | $44.3M | −25.4% | 6 |
| Next fiscal year (2027) | $16.9M | $0 | $58.5M | −54.4% | 6 |
LXRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LXRX revenue: reported and forecast
LXRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.06 | −$0.06 | −$0.05 | −11.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.16 | −$0.16 | −$0.16 | −$0.16 | −$0.17 | +4.8% | 0 up · 2 down |
| Next fiscal year (2027) | −$0.21 | −$0.21 | −$0.21 | −$0.21 | −$0.19 | −7.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LXRX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LXRX beat in 11 of 12.
What analysts expect from LXRX
6 analysts cover Lexicon Pharmaceuticals; their consensus rating is buy (4.17 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.55, 199.1% above the latest close of $1.52. Analysts expect earnings of −$0.17 per share for 2026, −18.8% from a year earlier. For 2027 the average estimate is −$0.19 per share on revenue of $16.9 million. Lexicon Pharmaceuticals beat the EPS estimate in 11 of the last 12 quarters.
Related: LXRX income statement, LXRX key metrics, LXRX chart. See the LXRX stock overview for the latest quote and news.
LXRX forecast FAQ
What is Lexicon Pharmaceuticals's price target?
The average analyst price target for Lexicon Pharmaceuticals is $4.55, 199.1% above the latest close of $1.52.
Is Lexicon Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Lexicon Pharmaceuticals, 3 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Lexicon Pharmaceuticals's EPS forecast?
Analysts forecast −$0.17 per share for 2026 (range −$0.18 to −$0.15); for 2027 the estimate is −$0.19.
What is Lexicon Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $37.2 million, growth of −25.4%; for 2027 it is $16.9 million.
When does Lexicon Pharmaceuticals report earnings?
Lexicon Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.05.
Does Lexicon Pharmaceuticals usually beat earnings estimates?
Lexicon Pharmaceuticals reported EPS at or above the analyst estimate in 11 of the last 12 quarters.